Comparison of four pancreatic extracts in cystic fibrosis

• Published in: Archives of disease in childhood Vol. 62; no. 6; pp. 564 - 568
• Main Authors: Beverley, D W, Kelleher, J, MacDonald, A, Littlewood, J M, Robinson, T, Walters, M P
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health 01.06.1987; BMJ; BMJ Publishing Group LTD
• Subjects: Absorption; Adolescent; Adult; Biological and medical sciences; Celiac Disease - chemically induced; Child; Clinical Trials as Topic; Cystic Fibrosis - drug therapy; Delayed-Action Preparations; Dietary Fats - metabolism; Dietary restrictions; Feces - analysis; Humans; Intestinal Absorption; Medical sciences; Nitrogen - analysis; Pancreatin - adverse effects; Pancreatin - therapeutic use; Pharmacology. Drug treatments; Random Allocation; Respiratory system; Human; Chemotherapy; Mucoviscidosis; Respiratory disease; Formulation; Digestive diseases; Extract; Pancreas; Child; Comparative study
• ISSN: 0003-9888; 1468-2044
• DOI: 10.1136/adc.62.6.564

Four different pancreatin products, Pancrease, Creon, Pancrex V Forte, and Pancreatin Merck, were compared in a random crossover trial in children with cystic fibrosis. The results of our study showed that patients who received Creon and Pancrease had fewer gastrointestinal symptoms than patients who received Pancrex V Forte and Pancreatin Merck. Fat absorption was significantly improved with Pancrease when compared with Pancrex V forte and Pancreatin Merck. Also the fat absorption with Creon was superior to that with Pancrex V Forte. There was no significant difference in fat absorption between Pancrease and Creon. Pancrex V Forte and Pancreatin Merck, or Pancreatin Merck and Creon. Faecal nitrogen content was less with both Creon and Pancrease compared with Pancreatin Merck. Creon and Pancrease allow the patient with cystic fibrosis to take a high energy diet without any dietary restrictions.